Singapore markets closed
Straits Times Index
3,227.10 -35.97 (-1.10%) Nikkei
27,153.83 -159.30 (-0.58%) Hang Seng
17,933.27 -214.68 (-1.18%) FTSE 100
7,018.60 -140.92 (-1.97%) BTC-USD
19,125.04 +208.08 (+1.10%) CMC Crypto 200
434.61 -9.92 (-2.23%)
Roche Holding AG (RHHVF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 03:43PM EDT
| Previous close | 320.00 |
| Open | 312.74 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 312.74 - 330.14 |
| 52-week range | 299.01 - 430.00 |
| Volume | |
| Avg. volume | 6,131 |
| Market cap | 260.368B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 18.07 |
| EPS (TTM) | 18.27 |
| Earnings date | N/A |
| Forward dividend & yield | 9.97 (3.02%) |
| Ex-dividend date | 17 Mar 2022 |
| 1y target est | N/A |
- Zacks
Pharma Stock Roundup: EU Nod to AZN & RHHBY Drugs, FDA Updates for LLY & MRK
Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.
- Zacks
Novartis (NVS) to Appeal to Supreme Court for Gilenya Patent
Novartis (NVS) is looking to defend its patents for the multiple sclerosis drug Gilenya and file a petition in the Supreme Court after an unfavorable ruling in the federal court.
- Zacks
Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe
The European Commission approves Roche's (RHHBY) Vabysmo for treating neovascular or wet age-related macular degeneration and visual impairment due to diabetic macular edema.
© 2022 Yahoo. All rights reserved.
